The drug "Tsernilton" (an analogue of theregistered) is issued in the form of biconvex, round tablets. The color is light or pale yellow. The tablets have small, more dark inclusions. The agent "Cernilton" has a specific smell. The preparation has a plant basis.
Cernilton. Instructions
The drug is used for benign prostatic hyperplasia.
The drug has anti-edematous and anti-inflammatory effect, actively promotes the regulation of metabolic (metabolic) processes.
The drug "Cernilton" (reviews and commentsexperts confirm this) has a number of useful properties, due to which the synthesis of inflammatory mediators in the arachidonic acid cycle: leukotrienes and prostaglandins is slowed down.
As a result, there is a decrease in edema and inflammation in the prostate tissue.
The agent "Cernilton" (patient reviews indicate this) helps to reduce the intensity of the pain syndrome.
The agent helps to reduce the volume of the prostate,carries out blocking of alpha-1 adrenoreceptors of smooth muscle components in the urethra, has antiandrogenic activity. The drug "Cernilton" (patients' reviews also confirm this) contribute to the normalization of erectile function.
The agent is shown in the complex therapy for chronic and acute prostatitis, prostate hyperplasia of benign nature, including in combination with prostatitis.
The drug "Cernilton" (reviews of doctors are unambiguous in that) is not allowed for administration in the presence of hypersensitivity to components.
The remedy is recommended for ingestion before meals (usually for half an hour). Tablets are washed down with water in small amounts.
With an acute prostatitis, usually three times a day, four tablets are administered. The duration of therapy is determined by the doctor. As a rule, the duration of admission is three months.
With prostatitis chronic course recommended by the tablet three to four times a day. The duration of therapy can be from three to six months.
When prostatic hyperplasia is benigncharacter appoint three times a day for two tablets. The duration of therapy is usually six to twelve weeks, but if necessary, it can be increased to six months.
In clinical practice, no cases of overdose have been documented. There are also no clinically relevant information about the interaction of the drug with other medicines.
The administration of the agent in case of chronic prostatitis of bacterial nature is allowed only in combination with antibacterial agents. Therapy in this case should be supervised by a specialist.
